Development and validation of a deprescribing tool relevant to older persons in India using modified Delphi consensus technique
Authors:
- Ratinder JhajRJRatinder Jhaj
- Santanu Kumar TripathiSTSantanu Kumar Tripathi
- Minakshi DharMDMinakshi Dhar
- Rajnish JoshiRJRajnish Joshi
- Snehil GuptaSGSnehil Gupta
- Rehan Ul-HaqRURehan Ul-Haq
- Danish JavedDJDanish Javed
- Ajay Kumar ShuklaASAjay Kumar Shukla
- Shubham AtalSAShubham Atal
- Anindo MajumdarAMAnindo Majumdar
Open Access
- 2 December 2025
- journal article
- research article
- Published by Springer Nature in BMC Geriatrics
- Vol. 25 (1) , 991
Abstract
Background: Polypharmacy is common in older persons, and some of the prescribed drugs may be potentially inappropriate medications (PIMs), whose risks outweigh their benefits. It is therefore necessary to review medication intake of older patients and deprescribe the ones that are not appropriate. Although there are many tools for deprescribing, none of these have been developed for the Indian context, where there is widespread use of fixed dose combinations (FDCs), medicines from different systems of medicines, and different levels of healthcare. Also, some of the medications listed in existing tools are not marketed in India, while some which are commonly prescribed in the country are not listed in the tools. We therefore undertook to develop a deprescribing tool for the older persons in India. Methods: A draft deprescribing tool was developed through a modified Delphi consensus process by 18 panellists. Item level content validity index (I-CVI) and scale level content validity index (S-CVI) were calculated from the Delphi round 1 and 2 responses. In addition, face and content validity of the tool was carried out by 6 experts and content validity ratio (CVR’) and I-CVI were calculated. Results: Our draft Deprescribing tool included 63 drugs/groups organized in three sections-drugs/drug groups to avoid generally in all older patients (39 items), herb-drug interactions (5 interactions) and drugs which should be avoided in renal dysfunction (15 allopathic and 4 herbal medicines). After Delphi process and tool validation, ten drugs/drug groups were removed due to CVR’ value < 0.62 or I-CVI value < 0.67, and recommendations and/or alternatives were modified for nine drugs/groups, so that the final the tool includes 52 items – 30 drugs/drug groups to be avoided in all older persons, 7 herb-drug interactions and 15 drugs to be avoided in renal dysfunction. The scale-level content validity index (S-CVI) was 0.87 for the entire tool, which is higher than the generally acceptable 0.8. Conclusion: A deprescribing tool containing drugs/drug groups commonly prescribed and relevant for the older persons in India, including important herb-drug interactions, and restricted to drugs available and prescribed in India, has been developed through the Delphi process followed by tool validation.Keywords
Funding Information
- Indian Council of Medical Research (SRUM/2023/BMS/Part4/RatinderJhaj)
- Indian Council of Medical Research (SRUM/2023/BMS/Part4/RatinderJhaj)
This publication has 60 references indexed in Scilit:
- STOPP/START criteria for potentially inappropriate prescribing in older people: version 3European Geriatric Medicine, 2023
- Therapeutic dilemmas with benzodiazepines and Z-drugs: insomnia and anxiety disorders versus increased fall risk: a clinical reviewEuropean Geriatric Medicine, 2022
- Characterization of potentially inappropriate medications use in Indian elderly population and their impact on quality of life using Beers criteriaAging Medicine, 2022
- Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequencesEuropean Geriatric Medicine, 2021
- Deprescribing for Community-Dwelling Older Adults: a Systematic Review and Meta-analysisJournal of General Internal Medicine, 2020
- Deprescribing tools: a review of the types of tools available to aid deprescribing in clinical practiceJournal of Pharmacy Practice and Research, 2020
- Interventions to improve the appropriate use of polypharmacy for older peopleCochrane Database of Systematic Reviews, 2018
- Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasiaPharmacoepidemiology and Drug Safety, 2018
- The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countriesEuropean Journal of Clinical Pharmacology, 2015
- Use of Alternative Medicine by Patients With Stage 5 Chronic Kidney DiseaseAdvances in Chronic Kidney Disease, 2005